Pancreatic Cancer Research

ResearcherUniversity of Nebraska–LincolnActive in the last 2 years

Surendra Kumar Shukla

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4490-8013; OpenAlex author ID A5059676224; NIH RePORTER profile ID 11842149. Sources: OpenAlex.

Their work

Papers
28 (first author 4, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
71
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 5 papers · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers, 1 grant

Papers 28

  1. KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1984↗
  2. Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02340-8↗
  3. Epigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications. Last author DOI 10.3389/freae.2025.1723159↗
  4. Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Co-author DOI 10.1016/j.ejmech.2024.116598↗
  5. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  6. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  7. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Co-author DOI 10.1073/pnas.2315509121↗
  8. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215981↗
  9. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. First author DOI 10.1038/s41388-021-02132-6↗
  10. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Co-author DOI 10.1038/s41598-022-05660-7↗
  11. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. First author DOI 10.1053/j.gastro.2021.06.045↗
  12. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  13. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2020.04.017↗
  14. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2020.07.025↗
  15. Evaluating the Metabolic Alterations in Pancreatic Cancer. First author DOI 10.1007/978-1-4939-8879-2_20↗
  16. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. Co-author DOI 10.1007/978-1-4939-8879-2_28↗
  17. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cancers11091327↗
  18. Metabolic Alterations in Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers12010002↗
  19. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2017.04.029↗
  20. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  21. Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.jproteome.7b00246↗
  22. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-16-3062↗
  23. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-1151↗
  24. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Co-author DOI 10.1021/acs.biomac.5b01419↗
  25. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Co-author DOI 10.18632/oncotarget.4078↗
  26. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Co-author DOI 10.18632/oncotarget.5843↗
  27. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Co-author DOI 10.18632/oncotarget.5935↗
  28. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Co-author DOI 10.1186/2049-3002-2-18↗

Grants 1

  1. Role of ZC3H15 in Pancreatic Cancer Pathogenesis and Therapeutic Response R01CA316828↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pankaj Kumar Singh · 25 shared papers, 2014–2026 · strength 2.48
  2. Ryan J. King · 13 shared papers, 2015–2026 · strength 1.33
  3. Kamiya Mehla · 11 shared papers, 2014–2026 · strength 1.32
  4. Ravi Kumar Thakur · 8 shared papers, 2021–2026 · strength 1.28
  5. Nina V. Chaika · 14 shared papers, 2014–2024 · strength 1.28
  6. Aneesha Dasgupta · 13 shared papers, 2015–2024 · strength 1.26
  7. Michael Anthony Hollingsworth · 9 shared papers, 2017–2026 · strength 1.18
  8. Chunbo He · 7 shared papers, 2021–2026 · strength 1.09
  9. Scott E. Mulder · 8 shared papers, 2017–2024 · strength 0.97
  10. Kuldeep Singh Attri · 8 shared papers, 2017–2024 · strength 0.94
  11. Divya Murthy · 8 shared papers, 2017–2024 · strength 0.90
  12. Tuo Hu · 5 shared papers, 2021–2026 · strength 0.81
  13. Paul M. Grandgenett · 7 shared papers, 2017–2024 · strength 0.77
  14. Venugopal Gunda · 11 shared papers, 2014–2022 · strength 0.75
  15. Enza Vernucci · 9 shared papers, 2015–2022 · strength 0.67
  16. Jaime Abrego · 9 shared papers, 2015–2022 · strength 0.67
  17. Sai Sundeep Kollala · 4 shared papers, 2023–2026 · strength 0.66
  18. Susanna Varkey Ulahannan · 3 shared papers, 2024–2026 · strength 0.50
  19. Robert Powers · 5 shared papers, 2014–2024 · strength 0.43
  20. Teklab Gebregiworgis · 5 shared papers, 2014–2024 · strength 0.43
  21. Spas Dimitrov Markov · 3 shared papers, 2020–2026 · strength 0.42
  22. Joshua J. Souchek · 5 shared papers, 2015–2024 · strength 0.42
  23. Voddu Suresh · 2 shared papers, 2024–2026 · strength 0.41
  24. Hina Sultana · 1 shared paper, 2025 · strength 0.37
  25. Vikrant Rai · 3 shared papers, 2019–2024 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.